{"classes":[{"categories":[{"measurements":[{"groupId":"OG000","spread":"11.80","value":"4.6"},{"groupId":"OG001","spread":"13.50","value":"3.9"}]}],"title":"Mental Health Score"},{"categories":[{"measurements":[{"groupId":"OG000","spread":"8.76","value":"6.4"},{"groupId":"OG001","spread":"8.97","value":"4.8"}]}],"title":"Physical Health Score"}],"denoms":[{"counts":[{"groupId":"OG000","value":"312"},{"groupId":"OG001","value":"154"}],"units":"Participants"}],"description":"The SF-36 is a questionnaire used to assess physical functioning and is made up of eight domains: Physical Functioning, Role Physical, Bodily Pain, General Health, Vitality, Social Functioning, Role-Emotional and Mental Health. Transforming and standardizing these domains leads to the calculation of the Physical (PCS) and Mental (MCS) Component Summary measures. Scores ranging from 0 to 100, with 0=worst score (or quality of life) and 100=best score. A positive change from baseline indicates improvement.","dispersionType":"Standard Deviation","groups":[{"description":"1000 mg rituximab intravenous initial treatment on day 1 and day 15 plus 10-25 mg/week methotrexate followed by re-treatment during weeks 24 -40 consisting of two additional doses of 1000 mg rituximab 14 days apart plus 10-25 mg/week methotrexate.","id":"OG000","title":"Arm A: Rituximab Re-treatment"},{"description":"1000 mg rituximab initial treatment on day 1 and day 15 plus 10-25 mg/wk methotrexate followed by re-treatment during weeks 24 -40 consisting of two doses of placebo 14 days apart plus 10-25 mg/wk methotrexate.","id":"OG001","title":"Arm B: Placebo Re-treatment"}],"paramType":"MEAN","populationDescription":"Participants from the Intent-to-treat population, that includes all participants randomized to Retreatment, with data available for analyses.","reportingStatus":"POSTED","timeFrame":"Baseline, Week 48","title":"Change From Baseline in SF-36 Health Summary Scores at Week 48 in Retreated Subjects","type":"SECONDARY","unitOfMeasure":"Score on a scale"}